Sugi Predict

Sugi Predict / Compounds / SCHEMBL15415674

SCHEMBL15415674

SCHEMBL15415674

[c]1nccc(N2CCCCCC2)n1

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ CYP1A2 P05177 1/20 0.40
▸ CXCR4 P61073 1/20 0.38
▸ CHKA P35790 1/20 0.38
▸ HRH4 Q9H3N8 1/20 0.37
▸ CNR2 P34972 4/20 0.36
▸ HPGD P15428 3/20 0.35
▸ CHRM3 P20309 1/20 0.34
▸ PDE4A P27815 1/20 0.34
▸ PDE4B Q07343 1/20 0.34
▸ PDE4C Q08493 1/20 0.34
▸ PDE4D Q08499 1/20 0.34
▸ ALDH1A1 P00352 4/20 0.34
▸ MAPT P10636 4/20 0.34
▸ SMN1; SMN2 Q16637 3/20 0.34
▸ NPC1 O15118 2/20 0.34
▸ RAB9A P51151 2/20 0.34
▸ MAPK1 P28482 2/20 0.34
▸ KDM4E B2RXH2 2/20 0.34
▸ GAA P10253 2/20 0.34
▸ LMNA P02545 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7303410 1.00 CYP1A2 (0.40) CYP1A2CXCR4CHKAHRH4CNR2
SCHEMBL1526838 0.98 CHKA (0.39) CYP1A2CXCR4CHKAHRH4CNR2
SCHEMBL15415235 0.94 CHKA (0.34) CYP1A2CXCR4CHKAHRH4CNR2
SCHEMBL1521529 0.81 ALDH1A1 (0.33) CNR2ALDH1A1MAPTRAB9AKDM4E
SCHEMBL1110243 0.81 PIK3CA (0.44) CYP1A2HPGDALDH1A1MAPTSMN1; SMN2
SCHEMBL934301 0.81 HRH4 (0.49) CYP1A2HRH4ALDH1A1KDM4ETSHR
SCHEMBL1110327 0.81 PLD1 (0.49) CYP1A2HRH4ALDH1A1MAPK1KDM4E
SCHEMBL12615573 0.77 RXFP1 (0.46) HPGDALDH1A1MAPTSMN1; SMN2NPC1
SCHEMBL12615235 0.77 MAP4K4 (0.44) HRH4
SCHEMBL12614647 0.77 SMPD3 (0.43) ALDH1A1NPC1KDM4EHSD17B10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 147 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11912721-B2 Fused pentacyclic imidazole derivatives UCB Biopharma SRL (BE) 2024-02-27 — — US disclosed
EP-3436456-B1 FUSED HEXACYCLIC IMIDAZOLE DERIVATIVES AS MODULATORS OF TNF ACTIVITY UCB Biopharma SRL (BE) 2021-11-17 — — EP disclosed
EP-3436460-B1 FUSED PENTACYCLIC IMIDAZOLE DERIVATIVES AS MODULATORS OF TNF ACTIVITY UCB Biopharma SRL (BE) 2021-08-18 — — EP disclosed
EP-3201196-B1 FUSED PENTACYCLIC IMIDAZOLE DERIVATIVES UCB Biopharma SRL (BE) 2021-07-28 — — EP disclosed
EP-3436458-B1 FUSED PENTACYCLIC IMIDAZOLE DERIVATIVES AS MODULATORS OF TNF ACTIVITY UCB Biopharma SRL (BE) 2021-06-02 — — EP disclosed
US-20210155637-A1 Fused Pentacyclic Imidazole Derivatives SANOFI (FR) 2021-05-27 — — US disclosed
US-10953019-B2 Fused pentacyclic imidazole derivatives as modulators of TNF activity UCB Biopharma SRL (BE) 2021-03-23 — — US disclosed
US-10906919-B2 Fused pentacyclic imidazole derivatives UCB Biopharma SRL (BE) 2021-02-02 — — US disclosed
US-10793578-B2 Fused pentacyclic imidazole derivatives as modulators of TNF activity UCB Biopharma SRL (BE) 2020-10-06 — — US disclosed
US-10766906-B2 Fused hexacyclic imidazole derivatives as modulators of TNF activity UCB Biopharma SRL (BE) 2020-09-08 — — US disclosed
WO-2015086508-A1 BENZOTRIAZOLE DERIVATIVES AS MODULATORS OF TNF ACTIVITY UCB BIOPHARMA SPRL (BE) 2015-06-18 — — WO disclosed
WO-2015086498-A1 TETRAHYDROIMIDAZOPYRIDINE DERIVATIVES AS MODULATORS OF TNF ACTIVITY UCB BIOPHARMA SPRL (BE) 2015-06-18 — — WO disclosed
WO-2015086505-A1 PURINE DERIVATIVES AS MODULATORS OF TNF ACTIVITY UCB BIOPHARMA SPRL (BE) 2015-06-18 — — WO disclosed
WO-2015086526-A1 FUSED TRICYCLIC IMIDAZOLE DERIVATIVES AS MODULATORS OF TNF ACTIVITY UCB BIOPHARMA SPRL (BE) 2015-06-18 — — WO disclosed
WO-2015086527-A1 FUSED TRICYCLIC IMIDAZOLE DERIVATIVES AS MODULATORS OF TNF ACTIVITY UCB BIOPHARMA SPRL (BE) 2015-06-18 — — WO disclosed
WO-2015086496-A1 TRIAZOLOPYRIDINE DERIVATIVES AS MODULATORS OF TNF ACTIVITY UCB BIOPHARMA SPRL (BE) 2015-06-18 — — WO disclosed
WO-2015086523-A1 FUSED BICYCLIC HETEROAROMATIC DERIVATIVES AS MODULATORS OF TNF ACTIVITY UCB BIOPHARMA SPRL (BE) 2015-06-18 — — WO disclosed
WO-2015086507-A1 IMIDAZOPYRIDINE DERIVATIVES AS MODULATORS OF TNF ACTIVITY UCB BIOPHARMA SPRL (BE) 2015-06-18 — — WO disclosed
EP-2872508-A1 IMIDAZOPYRIDINE DERIVATIVES AS MODULATORS OF TNF ACTIVITY UCB Biopharma SPRL (BE) 2015-05-20 — — EP disclosed
WO-2014009295-A1 IMIDAZOPYRIDINE DERIVATIVES AS MODULATORS OF TNF ACTIVITY UCB PHARMA S.A. (BE) 2014-01-16 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10906919-B2 Fused pentacyclic imidazole derivatives TNF, NFKBIA, TNFRSF1A CYP1A2 664/4885CXCR4 1595/4885CHKA 1244/4885
US-20210155637-A1 Fused Pentacyclic Imidazole Derivatives TNF, NFKBIA, TNFRSF1A CYP1A2 664/4885CXCR4 1595/4885CHKA 1244/4885
US-10953019-B2 Fused pentacyclic imidazole derivatives as modulators of TNF activity TNF, TNFRSF1A, NFKBIA CYP1A2 3245/4885CXCR4 1734/4885CHKA 684/4885
US-10766906-B2 Fused hexacyclic imidazole derivatives as modulators of TNF activity TNF, TNFRSF1A, NFKBIA CYP1A2 1016/4885CXCR4 366/4885CHKA 1225/4885
US-11912721-B2 Fused pentacyclic imidazole derivatives TNF, NFKBIA, TNFRSF1A CYP1A2 664/4885CXCR4 1595/4885CHKA 1244/4885
US-10793578-B2 Fused pentacyclic imidazole derivatives as modulators of TNF activity TNF, TNFRSF1A, NFKBIA CYP1A2 1964/4885CXCR4 1687/4885CHKA 765/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.